Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: Role in the cell cycle and apoptosis

Biochemical Pharmacology

Volumn 75, Issue 2, 2008, Pages 414-426

  Selga, Elisabet ^a   Noé, Véronique ^a   Ciudad, Carlos J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

AKR1C1; DHFR; Drug resistance; Methotrexate; Sp1 binding; Transcriptional regulation

Indexed keywords

ALDO KETO REDUCTASE; DIHYDRODIOL DEHYDROGENASE; MESSENGER RNA; METHOTREXATE; OXIDOREDUCTASE; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN HT29; DRUG RESISTANCE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSCRIPTION REGULATION;

20-HYDROXYSTEROID DEHYDROGENASES; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BASE SEQUENCE; CELL CYCLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; METHOTREXATE; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); RNA, SMALL INTERFERING; SP1 TRANSCRIPTION FACTOR; TETRAHYDROFOLATE DEHYDROGENASE; TRANSCRIPTION, GENETIC;

EID: 37349121900     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.08.034     Document Type: Article

References (44)

1. Wagner C. Symposium on the subcellular compartmentation of folate metabolism. J Nutr 126 Suppl. 4 (1996) 1228S-1234S
2. Huennekens F.M. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv Enzyme Regul 34 (1994) 397-419
3. Goldman I.D., and Matherly L.H. The cellular pharmacology of methotrexate. Pharmacol Ther 28 1 (1985) 77-102
4. Neumann K., Al-Batayneh K.M., Kuiper M.J., Parsons-Sheldrake J., Tyshenko M.G., Flintoff W.F., Cole S.P., and Walker V.K. A single point mutation in Drosophila dihydrofolate reductase confers methotrexate resistance to a transgenic CHO cell line. Genome 46 4 (2003) 707-715
5. Chu E., Grem J.L., Johnston P.G., and Allegra C.J. New concepts for the development and use of antifolates. Stem Cells 14 1 (1996) 41-46
6. Jolivet J., Cowan K.H., Curt G.A., Clendeninn N.J., and Chabner B.A. The pharmacology and clinical use of methotrexate. N Engl J Med 309 18 (1983) 1094-1104
7. de Nonancourt-Didion M., Gueant J.L., Adjalla C., Chery C., Hatier R., and Namour F. Overexpression of folate binding protein alpha is one of the mechanism explaining the adaptation of HT29 cells to high concentration of methotrexate. Cancer Lett 171 2 (2001) 139-145
8. Lesuffleur T., Barbat A., Luccioni C., Beaumatin J., Clair M., Kornowski A., et al. Dihydrofolate reductase gene amplification-associated shift of differentiation in methotrexate-adapted HT-29 cells. J Cell Biol 115 5 (1991) 1409-1418
9. Zeindl-Eberhart E., Klugbauer S., Dimitrijevic N., Jungblut P.R., Lamer S., and Rabes H.M. Proteome analysis of rat hepatomas: carcinogen-dependent tumor-associated protein variants. Electrophoresis 22 14 (2001) 3009-3018
10. Penning T.M. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr Rev 18 3 (1997) 281-305
11. Penning T.M. AKR1B10: a new diagnostic marker of non-small cell lung carcinoma in smokers. Clin Cancer Res 11 5 (2005) 1687-1690
12. Vergnes L., Phan J., Stolz A., and Reue K. A cluster of eight hydroxysteroid dehydrogenase genes belonging to the aldo-keto reductase supergene family on mouse chromosome 13. J Lipid Res 44 3 (2003) 503-511
13. Maser E. Xenobiotic carbonyl reduction and physiological steroid oxidoreduction. The pluripotency of several hydroxysteroid dehydrogenases. Biochem Pharmacol 49 4 (1995) 421-440
14. Burczynski M.E., Lin H.K., and Penning T.M. Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res 59 3 (1999) 607-614
15. O'Connor T., Ireland L.S., Harrison D.J., and Hayes J.D. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem J 343 Pt 2 (1999) 487-504
16. Jez J.M., Flynn T.G., and Penning T.M. A new nomenclature for the aldo-keto reductase superfamily. Biochem Pharmacol 54 6 (1997) 639-647
17. Hsu N.Y., Ho H.C., Chow K.C., Lin T.Y., Shih C.S., Wang L.S., et al. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res 61 6 (2001) 2727-2731
18. Wang L.S., Chow K.C., Wu Y.C., Lin T.Y., and Li W.Y. Inverse expression of dihydrodiol dehydrogenase and glutathione-S-transferase in patients with esophageal squamous cell carcinoma. Int J Cancer 111 2 (2004) 246-251
19. Zhang D., Tai L.K., Wong L.L., Chiu L.L., Sethi S.K., and Koay E.S. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 4 11 (2005) 1686-1696
20. Nagaraj N.S., Beckers S., Mensah J.K., Waigel S., Vigneswaran N., and Zacharias W. Cigarette smoke condensate induces cytochromes P450 and aldo-keto reductases in oral cancer cells. Toxicol Lett 165 2 (2006) 182-194
21. Yu D., Berlin J.A., Penning T.M., and Field J. Reactive oxygen species generated by PAH o-quinones cause change-in-function mutations in p53. Chem Res Toxicol 15 6 (2002) 832-842
22. Ax W., Soldan M., Koch L., and Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 59 3 (2000) 293-300
23. Deng H.B., Parekh H.K., Chow K.C., and Simpkins H. Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J Biol Chem 277 17 (2002) 15035-15043
24. Deng H.B., Adikari M., Parekh H.K., and Simpkins H. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase. Cancer Chemother Pharmacol 54 4 (2004) 301-307
25. Chen Y.J., Yuan C.C., Chow K.C., Wang P.H., Lai C.R., Yen M.S., et al. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Gynecol Oncol 97 1 (2005) 110-117
26. Hung J.J., Chow K.C., Wang H.W., and Wang L.S. Expression of dihydrodiol dehydrogenase and resistance to chemotherapy and radiotherapy in adenocarcinoma cells of lung. Anticancer Res 26 4B (2006) 2949-2955
27. Shen H., Kauvar L., and Tew K.D. Importance of glutathione and associated enzymes in drug response. Oncol Res 9 6-7 (1997) 295-302
28. Ciaccio P.J., Stuart J.E., and Tew K.D. Overproduction of a 37.5-kDa cytosolic protein structurally related to prostaglandin F synthase in ethacrynic acid-resistant human colon cells. Mol Pharmacol 43 6 (1993) 845-853
29. Rocke D.M., and Durbin B. A model for measurement error for gene expression arrays. J Comput Biol 8 6 (2001) 557-569
30. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
31. Ciudad C.J., Morris A.E., Jeng C., and Chasin L.A. Point mutational analysis of the hamster dihydrofolate reductase minimum promoter. J Biol Chem 267 6 (1992) 3650-3656
32. Noe V., Alemany C., Nicolas M., and Ciudad C.J. Sp1 involvement in the 4beta-phorbol 12-myristate 13-acetate (TPA)-mediated increase in resistance to methotrexate in Chinese hamster ovary cells. Eur J Biochem 268 11 (2001) 3163-3173
33. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 1-2 (1983) 55-63
34. Alt F.W., Kellems R.E., Bertino J.R., and Schimke R.T. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells, 1978. Biotechnology 24 (1992) 397-410
35. Curt G.A., Cowan K.H., and Chabner B.A. Gene amplification in drug resistance: of mice and men. J Clin Oncol 2 1 (1984) 62-64
36. Carman M.D., Schornagel J.H., Rivest R.S., Srimatkandada S., Portlock C.S., Duffy T., et al. Resistance to methotrexate due to gene amplification in a patient with acute leukemia. J Clin Oncol 2 1 (1984) 16-20
37. Coderre J.A., Beverley S.M., Schimke R.T., and Santi D.V. Overproduction of a bifunctional thymidylate synthetase-dihydrofolate reductase and DNA amplification in methotrexate-resistant Leishmania tropica. Proc Natl Acad Sci U S A 80 8 (1983) 2132-2136
38. Yamauchi A., Ichimiya T., Inoue K., Taguchi Y., Matsunaga N., Koyanagi S., et al. Cell-cycle-dependent pharmacology of methotrexate in HL-60. J Pharmacol Sci 99 4 (2005) 335-341
39. Chu S., and Ferro T.J. Sp1: regulation of gene expression by phosphorylation. Gene 348 (2005) 1-11
40. Wang H.W., Lin C.P., Chiu J.H., Chow K.C., Kuo K.T., Lin C.S., et al. Reversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug-resistance in nonsmall cell lung cancer cells by wogonin and chrysin. Int J Cancer 120 9 (2007) 2019-2027
41. Desmond J.C., Mountford J.C., Drayson M.T., Walker E.A., Hewison M., Ride J.P., et al. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Res 63 2 (2003) 505-512
42. Tanaka N.M., Shiota K., Noda K., Kadosawa T., Mochizuki M., Nishimura R., et al. Effects of 20 alpha-hydroxysteroid dehydrogenase and its inhibitors on canine osteosarcoma cell growth in vitro. J Vet Med Sci 58 7 (1996) 623-627
43. Chow K.C., Lu M.P., and Wu M.T. Expression of dihydrodiol dehydrogenase plays important roles in apoptosis- and drug-resistance of A431 squamous cell carcinoma. J Dermatol Sci 41 3 (2006) 205-212
44. Li D., Hinshelwood A., Gardner R., McGarvie G., and Ellis E.M. Mouse aldo-keto reductase AKR7A5 protects V79 cells against 4-hydroxynonenal-induced apoptosis. Toxicology 226 2-3 (2006) 172-180